<DOC>
	<DOCNO>NCT00045435</DOCNO>
	<brief_summary>This phase II trial study well reduce intensity donor peripheral blood stem cell ( PBSC ) transplant work treat patient de novo secondary acute myeloid leukemia ( AML ) remission . Giving low dos chemotherapy , fludarabine phosphate , total-body irradiation ( TBI ) donor PBSC transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen</brief_summary>
	<brief_title>Reduced Intensity Donor Peripheral Blood Stem Cell Transplant Treating Patients With De Novo Secondary Acute Myeloid Leukemia Remission</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine one-year disease free survival &gt; = 35 % achieve among patient &gt; = 55 year old de novo secondary AML first complete remission ( CR1 ) undergo nonmyeloablative hematopoietic stem cell transplant ( HSCT ) human leukocyte antigen ( HLA ) identical related donor . II . To determine day +200 nonrelapse related mortality &lt; 15 % achieve among patient &gt; = 55 year old de novo secondary AML CR1 undergo nonmyeloablative HSCT HLA identical related donor . OUTLINE : CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 undergo TBI day 0 . TRANSPLANT : Patients undergo allogeneic PBSC transplant day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine ( CSP ) orally ( PO ) twice daily ( BID ) day -3 56 taper day 77 . Patients also receive mycophenolate mofetil ( MMF ) PO BID day 0-27 . After completion study treatment , patient follow day 28 , 56 , 84 ; month 6 , 12 , 18 , 24 ; yearly 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients de novo AML ( FrenchAmericanBritish [ FAB ] MOM2 , M4M7 ) secondary AML achieve CR1 induction chemotherapy one two cycle consolidation chemotherapy Transplant conditioning must occur within 6 month diagnosis Patient enrollment must approve Fred Hutchinson Cancer Research Center ( FHCRC ) principal investigator ( PI ) PI 's designee DONOR : Related donor genotypically phenotypically identical DONOR : Age &gt; = 12 year DONOR : Donor must consent filgrastim ( GCSF ) administration leukapheresis DONOR : Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) AML FAB M3 AML involvement central nervous system ( CNS ) define positive cytospin cerebral spinal fluid time enrollment Presence circulate leukemic blast ( peripheral blood ) detect standard pathology Human immunodeficiency virus ( HIV ) seropositivity Fungal infection radiographic progression receipt amphotericin B active triazole great one month Diffusion capacity carbon monoxide ( DLCO ) correct &lt; 40 % Total lung capacity ( TLC ) &lt; 40 % Forced expiratory volume one second ( FEV1 ) &lt; 40 % require supplementary oxygen The FHCRC principal investigator study must approve enrollment patient pulmonary nodule Cardiac ejection fraction &lt; 40 % Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , bridge fibrosis , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3mg/dL , symptomatic biliary disease Karnofsky Performance Score &lt; 70 Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant breastfeeding No intensive chemotherapy give within three week ( interval cycle standard chemotherapy would administer nontransplant setting ) prior initiate nonmyeloablative transplant conditioning Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence Patients active bacterial fungal infection unresponsive medical therapy DONOR : Identical twin DONOR : Pregnancy DONOR : HIV seropositivity DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>